Trial Profile
Japan/Korea Joint Phase II Study of Nimotuzumab plus Irinotecan in Patients with Advanced or Recurrent Gastric Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2016
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Irinotecan
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Europe
- 19 Jun 2015 Status changed from active, no longer recruiting to completed.
- 22 Jan 2011 Preliminary results presented at the 2011 Gastrointestinal Cancers Symposium.
- 20 Jan 2011 Results were presented at the ASCO Gastrointestinal Cancer Symposium on January 20, according to a YM BioSciences media release